Abstract
After smoking cessation, bronchodilators are first-line therapy in the treatment of chronic obstructive pulmonary disease (COPD) [1]. Among the bronchodilators currently available, selective h-adrenergic receptor agonists have been extensively used over the last 30 years. An interesting paradox is that lack of response to h-agonists has often been used to define patients with COPD, particularly in clinical trials. This has often led to a general impression that treatment of COPD offers little benefit. Available data, however, clearly demonstrate that the majority of COPD patients respond to bronchodilators, including h-agonists [2,3]. Moreover, evidence is accumulating that h-agonists may benefit patients by mechanisms different from simple bronchodilatation. This chapter will review the current understanding of h-agonist bronchodilators and their role in the treatment of COPD.
Original language | English (US) |
---|---|
Title of host publication | Pharmacotherapy in Chronic Obstructive Pulmonary Disease |
Publisher | CRC Press |
Pages | 217-238 |
Number of pages | 22 |
ISBN (Electronic) | 9780203913406 |
ISBN (Print) | 9780824740290 |
State | Published - Jan 1 2003 |
ASJC Scopus subject areas
- Medicine(all)